Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 -...
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin...
DUBLIN, Ireland, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to...
Additional Capital Will Help Fund Development of PAX-101 TARRYTOWN, NY, Feb. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica,...
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader...
SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission...
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue...
Trading on the OTCQB Effective February 2, 2023, under the Symbol “FTHWF”TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Field Trip...
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ETHAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE)...
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for...
Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full...
ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en...
TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”)...
Company unifies video surveillance, access control, license plate recognition and more to improve security and the resident experience MONTRÉAL, February...